Are you paying attention Mr. Ricks?

Way back at the beginning of the year while attending the JP Morgan Healthcare conference we asked Dave Ricks Lilly’s (NYSE: LLY) CEO how the company planned to deal with the launch of Amedlog from Sanofi (NYSE: SNY). We asked simply why Sanofi would not do to Lilly in the short-acting insulin space with Amedlog what Lilly had done to Sanofi in the long-acting segment with Basaglar. The answer was underwhelming with Mr. Ricks basically saying he wasn’t that worried. Well he should be.